Adicet Bio Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$76.4M
Lead Investor(s):N/A

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Adicet Bio's estimated annual revenue is currently $14.3M per year.(?)
  • Adicet Bio's estimated revenue per employee is $201,000
  • Adicet Bio's total funding is $76.4M.

Employee Data

  • Adicet Bio has 71 Employees.(?)
  • Adicet Bio grew their employee count by 1% last year.
  • Adicet Bio currently has 7 job openings.

Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs). Adicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs can be used to arm T cells, as T cell engagers or as Antibody Drug Conjugates (ADC). In August 2016, Adicet entered a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology. Adicet Bio raised $51M in series A financing led by OrbiMed Partners, OrbiMed Israel, Novartis Venture Fund and Pontifax.